Humanized monoclonal antibody (mAb) therapeutics for the treatment of solid tumors, licensed exclusively from the University of Texas MD Anderson Cancer Center. Viba mAbs target a validated pathway which initiates and drives the progression and metastasis of numerous malignancies, including breast, pancreatic, ovarian, prostate, and colorectal cancer, and effect substantial increases in overall survival and tumor regression as single-agent therapy in highly-stringent animal models of advanced cancer which is refractory to standard-of-care treatment.
Small molecule inhibitors of a highly-validated target in the ceramide biosynthesis pathway, for the treatment of NASH, dyslipidemia, type 2 diabetes, and other metabolic diseases. Inhibition of this target by a small molecule tool compound in animals reverses insulin resistance and completely cures fatty liver disease.
Small molecule immuno-oncology agents for the treatment of solid tumors and hematologic malignancies. Celmune compounds target an immune cell population and pathway which contribute to a highly immunosuppressive tumor microenvironment that enables cancer cells to evade detection by the immune system. Tool compounds targeting this pathway effect substantial tumor regression and decreased metastasis in highly-stringent tumor models in animals having intact immune systems.